No Data
Guangdong Zhongsheng Pharmaceutical (002317): Innovative Drugs have entered the realization phase with stable development in traditional Business.
Core logic: The company has entered the phase of delivering its Innovative Drugs layout. There is a bullish outlook on the sales ramp-up after the approval and market launch of the influenza drug Anladiwei, and optimism regarding the overseas licensing potential of GLP-1R/GIPR dual-target weight loss and blood sugar reduction drugs. Weight loss/blood sugar reduction drugs: GLP-
A-shares show unusual activity丨Traditional Chinese Medicine stocks all rose, with Guangdong Zhongsheng Pharmaceutical and several other stocks hitting the daily limit, as the State Council emphasized increasing support for the research and innovation of T
On January 6, in the A-share market, the Traditional Chinese Medicine Sector rose against the trend, with Datang Pharmaceutical rising nearly 19%, Shanghai Kaibao Pharmaceutical rising over 16%, Xiangxue Pharmaceutical rising over 14%, Henan Taloph Pharmaceutical Stock, Shijiazhuang Yiling Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Guangdong Zhongsheng Pharmaceutical hitting the 10% limit up, Shanghai Shenqi Pharmaceutical Investment Management rising 9%, Jinghua Pharmaceutical Group, Tianjin Chase Sun Pharmaceutical, and Jiangxi Wannianqing Cement rising over 8%, Guizhou Sanli Pharmaceutical Co.,Ltd., Biovalley, and Guizhou Xinbang Pharmaceutical rising over 7%, Shandong Wohua Pharmaceutical and Sunflower Pharmaceutical Group rising over 6%, Zhejiang Xinguang Pharmaceutical, Oukang Pharmaceutical, Gansu Longshenrongfa Pharmaceutical Industry, and Guilin Sanjin Pharmaceutical rising over 5%, Guiyang Xintian Pharmaceutical, Zhejiang Wecome Pharmaceutical, Chongqing Taiji Industry, and Hubei Jumpca
Express News | The flu Concept is active at the beginning of trading, Shandong Lukang Pharmaceutical has two consecutive limit ups.
The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.
① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Zhongsheng Pharmaceutical (002317.SZ): Proposed to redeem part of the shares of the holding subsidiary Zhongsheng Ruichuang
On December 23, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that the company received notification from its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), regarding the Other Shareholders, including Huzhou Jingxin Private Equity Partnership (Limited Partnership), Hangzhou Xiangkang Yifeng Venture Capital Partnership (Limited Partnership), Guangzhou Yichuangda Venture Capital Partnership (Limited Partnership), Shenzhen Yifeng Yijing Venture Capital Partnership (Limited Partnership), Wuhan Yifeng Zhuohua Venture Capital Partnership (Limited Partnership), Wanlian Guangsheng Investment Co., Ltd., and Guangzhou Biological Island Industrial Investment Fund Partnership (Limited).
